Kanuma

Active Ingredient(s): Sebelipase Alfa
FDA Approved: * December 8, 2015
Pharm Company: * ALEXION PHARM

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kanuma Overview

Sebelipase alfa is a recombinant form of the enzyme lysosomal acid lipase (LAL) that was approved in 2015 under the tradename Kanuma in the US and EU for the treatment of people with lysosomal acid lipase deficiency (LAL-D).[1] Sebelipase was developed by Synageva that became part of Alexion Pharmaceuticals in 2015. For its production, chickens are genetically modified to produce the recombinant form of LAL (rhLAL) in their egg white. After extraction and purification it be...

Read more Kanuma Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sebelipase_alfa

Recent Kanuma Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Kanuma: (1 result)

Sorted by National Drug Code

• 25682-007 Kanuma 2 mg/ml Intravenous Injection, Solution, Concentrate by Alexion Pharmaceuticals, Inc.

Other drugs which contain Sebelipase Alfa or a similar ingredient: (1 result)

• SEBELIPASE ALFA